Search Within

Neil Jayendra Shah

Formats
  1. Meeting Abstract (53)
  2. Journal Article (27)
  3. Conference Paper (1)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (83)
  2. Genitourinary Oncology Service (83)
  3. Solid Tumor Oncology Division (83)
  4. Hematologic Malignancies, Division of (31)
  5. Weinberg Fellows (31)
  6. Population Sciences Research Program (25)

More Groups

People
  1. Robert Motzer (37)
  2. Ritesh Kotecha (26)
  3. Martin Voss (25)
  4. Maria Carlo (22)
  5. Darren Feldman (21)
  6. Chung-Han Lee (20)

More People

Years
  1. 2025 (8)
  2. 2024 (19)
  3. 2023 (22)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (44)
  2. Journal for ImmunoTherapy of Cancer (7)
  3. Cancers (4)
  4. The Oncologist (3)
  5. Annals of Oncology (2)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (46)
  2. Biomed Central Ltd (7)
  3. Oxford University Press (6)
  4. MDPI (5)
  5. American Association for Cancer Research (3)
  6. American Medical Association (2)

More Publishers

Results (83)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IL12/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events
    Journal Article

    Gu, S. L.; Maier, T.; Moy, A. P.; Dusza, S.; Faleck, D. M.; Shah, N. J.; Lacouture, M. E.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; Garmezy, B.; O'Neil, B.; Michalski, J.; Barata, P.; Bajaj, A.; Chahoud, J.; Liu, M.; Xu, F.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs)
    Meeting Abstract

    Maier, T.; Gu, S.; Shah, N. J.; Faleck, D. M.; Lacouture, M. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes
    Meeting Abstract

    Derry-Vick, H.; Zaemes, J. P.; Ahn, J.; Pascual, L.; Sinclaire, B.; Lev-Ari, S.; Alaoui, A.; Sridhar, A.; Adams, D.; Della Pia, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Big data in oncology: Challenges and solutions
    Meeting Abstract

    Shah, N. J.; Bahadur, N.; Niederhausern, A.; Insinga, A.; Shah, I.; West, G.; Ahmad, H.; Martin, S.; Watson, A.; Nichols, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
    Meeting Abstract

    Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Beckermann, K.; Campbell, M. T.; Haas, N. B.; Ornstein, M. C.; Gao, X.; Mao, S. S.; Hammers, H. J.; George, S.; Nelson, A. A.; Gourdin, T. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save